Compare CUK & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUK | WST |
|---|---|---|
| Founded | 1972 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 20.2B |
| IPO Year | 2000 | N/A |
| Metric | CUK | WST |
|---|---|---|
| Price | $26.04 | $269.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 10 |
| Target Price | $35.00 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 2.0M | 663.1K |
| Earning Date | 12-19-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 0.33% |
| EPS Growth | ★ 61.65 | 0.17 |
| EPS | 1.94 | ★ 6.75 |
| Revenue | ★ $26,230,000,000.00 | $3,017,900,000.00 |
| Revenue This Year | $9.50 | $7.01 |
| Revenue Next Year | $3.88 | $6.20 |
| P/E Ratio | ★ $13.93 | $39.46 |
| Revenue Growth | ★ 7.15 | 4.92 |
| 52 Week Low | $13.65 | $187.43 |
| 52 Week High | $29.80 | $348.90 |
| Indicator | CUK | WST |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 47.77 |
| Support Level | $23.34 | $265.39 |
| Resistance Level | $26.79 | $274.56 |
| Average True Range (ATR) | 0.63 | 7.58 |
| MACD | 0.36 | -0.69 |
| Stochastic Oscillator | 79.71 | 25.90 |
Carnival is the largest global cruise company, with more than 90 ships in service. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It recently folded its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.